Life Sciences Tools and Services

CDT Equity

CDT Equity released FY2025 9 Months Earnings on November 13 (EST), with actual revenue of USD 0 and EPS of USD -215.7827

CDT Equity released FY2025 Q3 earnings on November 13 (EST) with actual revenue of USD 0 and EPS of USD -13.161

CDT Equity released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -126.1688

CDT Equity released FY2025 Q2 earnings on August 14 (EST) with actual revenue of USD 0 and EPS of USD -5.4626

Conduit Submits Patent Application for AZD5658 Composition of Matter

Conduit Signs Joint Development Agreement with Manoira for Animal Health

Conduit Pharmaceuticals and Manoira Partner on Animal Health Drugs

Conduit Pharmaceuticals released FY2025 Q1 earnings on May 15, 2025 (EST) with actual revenue of USD 0 and EPS of USD -19.8648

Conduit Pharmaceuticals Secures 20-Year Patent for New Solid Form of AZD5904

Conduit Pharmaceuticals Inc. Submits Ownership Interest Statement

Conduit Pharmaceuticals Authorized to Set Reverse Stock Split Ratio

Conduit Pharmaceuticals Files IPO Prospectus

Conduit Pharmaceuticals Submits VTAMA® Co-Crystal Patent

Conduit Pharmaceuticals Announces Up to $1 Million Stock Buyback Plan

Conduit Pharmaceuticals Inc. Announces AZD1656 Patent Granted by USPTO, Plans to Advance Clinical Development

Conduit Pharmaceuticals released FY2024 Annual Earnings on March 28 (EST), actual revenue USD 0, actual EPS USD -307.9611

CDT Equity released FY2024 Q4 earnings on March 28, 2025 (EST), actual revenue USD 0, actual EPS USD 0

Conduit Pharmaceuticals Inc. Submits Nasdaq Compliance Plan and Receives Extension

Conduit Pharmaceuticals Inc. repays $600,000 promissory note and converts $1.7 million debt into common stock

Conduit Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST) with actual revenue of USD 0 and EPS of USD -111.199

Vision Marine Tech

AMC Robotics

B Riley Financial

Cementos Pacasmayo Saa 

Everbright Digital

Adagio Medical

Emerald

ChowChow Cloud

AdvisorShares MSOS 2x Daily ETF

Biodexa Pharmaceuticals

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap